FDA Extends Review Timeline for Denali Therapeutics’ Tividenofusp Alfa in Hunter Syndrome
Denali Therapeutics (Nasdaq: DNLI) announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its Biologics License Application (BLA) for tividenofusp alfa, an investigational therapy…